“High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept

References

• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.26667336
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM classification for lung cancer. J Thoracic Oncol. 2016;11:39–51. doi:10.1016/j.jtho.2015.09.009
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288–300. doi:10.21037/tlcr.2016.06.0727413711
   PubMed Web of Science ®Google Scholar
• Paesmans M. Prognostic and predictive factors for lung cancer. Breathe. 2012;9:112. doi:10.1183/20734735.006911
   Google Scholar
• Brierley JGM, Wittekind CH. TNM Classification of Malignant Tumours. 8th ed. Oxford UK, Hoboken NJ, eds. John Wiley & Sons, Inc; 2017.
   Google Scholar
• Moumtzi D, Lampaki S, Zarogoulidis P, et al. Prognostic factors for long term survival in patients with advanced non-small cell lung cancer. Ann Transl Med. 2016;4:161. doi:10.21037/atm.2016.05.1327275474
   PubMed Web of Science ®Google Scholar
• Wang B, Zeng J, Liu Y. Using nomograms to predict prognostic factors in young colorectal mucinous and signet-ring cell adenocarcinoma patients. Biosci Rep. 2019;39.
   Web of Science ®Google Scholar
• Zeng B, Ji P, Chen C, et al. A nomogram from the SEER database for predicting the prognosis of patients with non-small cell lung cancer. Int J Biochem Cell Biol. 2020;127:105825. doi:10.1016/j.biocel.2020.10582532898690
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377:849–861. doi:10.1056/NEJMra170341328854088
   PubMed Web of Science ®Google Scholar
• Ashour Badawy A, Khedr G, Omar A, et al. Site of metastases as prognostic factors in unselected population of stage iv non-small cell lung cancer. Asian Pacific j Cancer Prevent. 2018;19:1907–1910. doi:10.22034/APJCP.2018.19.7.1907
   PubMedGoogle Scholar
• Li J, Zhu H, Sun L, et al. Prognostic value of site-specific metastases in lung cancer: a population based study. J Cancer. 2019;10:3079–3086. doi:10.7150/jca.3046331289577
   PubMed Web of Science ®Google Scholar
• Motta G, Carbone E, Spinelli E, et al. Considerations about tumor size as a factor of prognosis in NSCLC. Ann Ital Chir. 1999;70:893–897.10804668
   PubMedGoogle Scholar
• Oh Y, Taylor S, Bekele BN, et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009;115:2930–2938. doi:10.1002/cncr.2433319441110
   PubMed Web of Science ®Google Scholar
• Zhang J, Gold KA, Lin HY, et al. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thoracic Oncol. 2015;10:682–690. doi:10.1097/JTO.0000000000000456
   PubMed Web of Science ®Google Scholar
• Lee DS, Park KR, Kim SJ, et al. Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes. Tumour Biol. 2016;37:619–625. doi:10.1007/s13277-015-3776-526240025
   PubMedGoogle Scholar
• Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA oncol. 2018;4:351–357. doi:10.1001/jamaoncol.2017.477129327044
   PubMed Web of Science ®Google Scholar
• Kitadai R, Okuma Y, Hakozaki T, et al. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. J Cancer Res Clin Oncol. 2020;146:777–785. doi:10.1007/s00432-019-03104-w31828427
   PubMed Web of Science ®Google Scholar
• Gibson AJW, Li H, D’Silva A, et al. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer. Med Oncol. 2018;35:117. doi:10.1007/s12032-018-1182-830073425
   PubMed Web of Science ®Google Scholar
• Tamura T, Kurishima K, Nakazawa K, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol clin oncol. 2015;3:217–221. doi:10.3892/mco.2014.41025469298
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang Y, Sun X, et al. The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study. J Cancer Res Clin Oncol. 2018;144:1835–1842. doi:10.1007/s00432-018-2702-930003315
   PubMed Web of Science ®Google Scholar
• Ren Y, Dai C, Zheng H, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7:53245–53253. doi:10.18632/oncotarget.1064427449299
   PubMedGoogle Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label Phase 3 trial. Lancet Respir Med. 2019;7:387–401. doi:10.1016/S2213-2600(19)30084-030922878
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301. doi:10.1056/NEJMoa171694829863955
   PubMed Web of Science ®Google Scholar